Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - Cost-effectiveness analysis (vol 84, pg 752, 2000)

被引：0

|

作者：

Marchetti, M

Pistorio, A

Barosi, G

机构：

来源：

THROMBOSIS AND HAEMOSTASIS | 2000年 / 84卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1112 / 1112

页数：1

相关论文

共 50 条

[31] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
Vorobyev, P.
Krasnova, L.
Borisenko, O.
Lukyantseva, D.
Bashlakova, L.
VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
[32] Factor V Leiden mutation and pregancy-related venous thromboembolism: What is the exact risk? (vol 96, pg 14, 2006)
Biron-Andreani
THROMBOSIS AND HAEMOSTASIS, 2006, 96 (03) : 389 - 389
[33] Risk of venous thromboembolism in relatives of factor V Leiden and factor II G20210A carriers: A combined analysis of retrospective and prospective studies.
Oliveira, LCO
Rizzatti, EG
Inacio, RAS
Baggio, MS
Tavella, MH
Franco, RF
BLOOD, 2005, 106 (11) : 466A - 466A
[34] Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness
Dranitsaris, George
Shane, Lesley G.
Woodruff, Seth
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (01) : 68 - 75
[35] Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer - A cost-effectiveness analysis
Attanasio, E
Russo, P
Carunchio, G
Caprino, L
PHARMACOECONOMICS, 2001, 19 (01) : 57 - 68
[36] Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for CancerA Cost-Effectiveness Analysis
Ermanno Attanasio
Pierluigi Russo
Gabriella Carunchio
Luciano Caprino
PharmacoEconomics, 2001, 19 : 57 - 68
[37] The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies
Marchiori, Antonio
Mosena, Laura
Prins, Martin H.
Prandoni, Paolo
HAEMATOLOGICA, 2007, 92 (08) : 1107 - 1114
[38] COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN FOR EXTENDED THROMBOPROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) AFTER ELECTIVE TOTAL HIP REPLACEMENT (THR) SURGERY
Weitz, J.
Bernard, L.
Wakeford, C.
VALUE IN HEALTH, 2009, 12 (07) : A333 - A333
[39] Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis (vol 12, pg 639, 2001)
Boyanovsky, B
Russev, M
Ganev, V
Penev, M
Baleva, M
BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (01) : 75 - 75
[40] The efficacy and cost-effectiveness of enoxaparin versus rivaroxaban in the prevention of venous thromboembolism following total hip or knee arthroplasty: A meta-analysis
Xu, Joshua
Chang, David
Chui, Juanita
Cao, Jacob
Negus, Jonathan
JOURNAL OF ORTHOPAEDICS, 2022, 30 : 1 - 6

← 1 2 3 4 5 →